No annual revenue total was found in CLIMB BIO, INC.'s SEC filings.
Climb Bio, Inc. (CLYM) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$54.5 million. As of Jun 30, 2026 it held $239.2 million in cash and investments and $1.3 million in total debt.
Revenue
—
Net income (TTM)
$-57.62M
-23.2% vs year-ago TTM
Operating cash flow (TTM)
$-52.70M
-32.9% vs year-ago TTM
Free cash flow (TTM)
$-53.07M
-33.6% vs year-ago TTM
EPS (TTM)
$-0.82
-18.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
47.77M
-29.2% vs prior year
Net cash
$237.91M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLYM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wellesley Hills, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1768446
- Former names
- Eliem Therapeutics, Inc. (until Sep 20, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$67.9M | -$82.0M | -$40.3M | -$45.1M | -$35.7M |
| Net income | -$59.9M | -$73.9M | -$35.1M | -$45.2M | -$47.5M |
| Diluted EPS | -$0.88 | -$1.53 | -$1.30 | -$1.72 | — |
| Operating cash flow | -$54.4M | -$15.6M | -$20.6M | -$37.4M | -$36.1M |
| Free cash flow | -$54.5M | -$20.2M | — | — | — |
| Total assets | $167.7M | $217.2M | $110.5M | $135.0M | $173.2M |
| Total liabilities | $7.3M | $5.3M | $2.9M | $6.3M | $6.0M |
| Stockholders' equity | $160.5M | $211.9M | $107.6M | $128.7M | $167.2M |
| Cash and investments | $160.7M | $212.5M | $106.8M | $123.6M | $161.4M |
| Total debt | $541,000 | $532,000 | $349,000 | $480,000 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 3, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 13, 2026 |
All 323 Climb Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.